|
1
|
Caldera-Villalobos C, Garza-Veloz I,
Martínez-Avila N, Delgado-Enciso I, Ortiz-Castro Y, Cabral-Pacheco
GA and Martinez-Fierro ML: The coronavirus disease (COVID-19)
challenge in Mexico: A critical and forced reflection as
individuals and society. Front Public Health. 8:3372020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alene M, Yismaw L, Assemie MA, Ketema DB,
Mengist B, Kassie B and Birhan TY: Magnitude of asymptomatic
COVID-19 cases throughout the course of infection: A systematic
review and meta-analysis. PLoS One. 16:e02490902021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu Z and McGoogan JM: Characteristics of
and important lessons from the coronavirus disease 2019 (COVID-19)
outbreak in china: Summary of a report of 72314 cases from the
Chinese center for disease control and prevention. JAMA.
323:1239–1242. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delgado-Enciso I, Paz-Garcia J,
Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores
R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA,
Delgado-Enciso J, et al: Safety and efficacy of a COVID-19
treatment with nebulized and/or intravenous neutral electrolyzed
saline combined with usual medical care vs. usual medical care
alone: A randomized, open-label, controlled trial. Exp Ther Med.
22:9152021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fagni F, Simon D, Tascilar K, Schoenau V,
Sticherling M, Neurath MF and Schett G: COVID-19 and
immune-mediated inflammatory diseases: Effect of disease and
treatment on COVID-19 outcomes and vaccine responses. Lancet
Rheumatol. 3:e724–e736. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q,
Wu Y, Sun L and Xu Y: Prevalence and severity of corona virus
disease 2019 (COVID-19): A systematic review and meta-analysis. J
Clin Virol. 127:1043712020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tenforde MW, Kim SS, Lindsell CJ, Billig
Rose E, Shapiro NI, Files DC, Gibbs KW, Erickson HL, Steingrub JS,
Smithline HA, et al: Symptom duration and risk factors for delayed
return to usual health among outpatients with COVID-19 in a
multistate health care systems network-United States, March-June
2020. MMWR Morb Mortal Wkly Rep. 69:993–998. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Manjili RH, Zarei M, Habibi M and Manjili
MH: COVID-19 as an acute inflammatory disease. J Immunol.
205:12–19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vivarelli S, Falzone L, Torino F,
Scandurra G, Russo G, Bordonaro R, Pappalardo F, Spandidos DA,
Raciti G and Libra M: Immune-checkpoint inhibitors from cancer to
COVID-19: A promising avenue for the treatment of patients with
COVID-19 (Review). Int J Oncol. 58:145–157. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dehelean CA, Lazureanu V, Coricovac D,
Mioc M, Oancea R, Marcovici I, Pinzaru I, Soica C, Tsatsakis AM and
Cretu O: SARS-CoV-2: Repurposed drugs and novel therapeutic
approaches-insights into chemical structure-biological activity and
toxicological screening. J Clin Med. 9:20842020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nitulescu GM, Paunescu H, Moschos SA,
Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK,
Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to
treat SARS-CoV-2 infection: Mechanistic insights into current
COVID-19 therapies (Review). Int J Mol Med. 46:467–488. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stancioiu F, Papadakis GZ, Kteniadakis S,
Izotov BN, Coleman MD, Spandidos DA and Tsatsakis A: A dissection
of SARS-CoV2 with clinical implications (Review). Int J Mol Med.
46:489–508. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sherren PB, Ostermann M, Agarwal S,
Meadows CIS, Ioannou N and Camporota L: COVID-19-related organ
dysfunction and management strategies on the intensive care unit: A
narrative review. Br J Anaesth. 125:912–925. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsatsakis A, Calina D, Falzone L, Petrakis
D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, et
al: SARS-CoV-2 pathophysiology and its clinical implications: An
integrative overview of the pharmacotherapeutic management of
COVID-19. Food Chem Toxicol. 146:1117692020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore N, Bosco-Levy P, Thurin N, Blin P
and Droz-Perroteau C: NSAIDs and COVID-19: A systematic review and
meta-analysis. Drug Saf. 44:929–938. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kelleni MT: Early use of non-steroidal
anti-inflammatory drugs in COVID-19 might reverse pathogenesis,
prevent complications and improve clinical outcomes. Biomed
Pharmacother. 133:1109822021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tripathi SK and Kasture PN: Mefenamic
acid: The evolution of a versatile NSAID. Indian J Clin Pract.
32:115–123. 2021.
|
|
18
|
Aggarwal KK: Mefenamic acid as
steroid-sparing anti-inflammatory drug during viral phase of
Covid-19: 5 case reports. Indian J Clin Pract. 31:759–763.
2021.
|
|
19
|
Rothan HA, Buckle MJ, Ammar YA,
Mohammadjavad P, Shatrah O, Noorsaadah AR and Rohana Y: Study the
antiviral activity of some derivatives of tetracycline and
non-steroid anti inflammatory drugs towards dengue virus. Trop
Biomed. 30:681–690. 2013.PubMed/NCBI
|
|
20
|
Aggarwal KK, Chong YW, Sharma R, Pillai M,
Naidu R, Chan AY, Urabe MU, Cavalcanti D, Budhathoky P, Sajjad Q,
et al: Repurposing mefenamic acid in the management of covid-19. J
Indian Med Assoc. 119:16–23. 2021.
|
|
21
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Salepci E, Turk B, Ozcan SN, Bektas ME,
Aybal A, Dokmetas I and Turgut S: Symptomatology of COVID-19 from
the otorhinolaryngology perspective: A survey of 223 SARS-CoV-2
RNA-positive patients. Eur Arch Otorhinolaryngol. 278:525–535.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
World Health Organization, . Clinical
Management of COVID-19: Interim guidance. 27–May. 2020, World
Health Organization; Geneva: 2020
|
|
24
|
Rivett L, Sridhar S, Sparkes D, Routledge
M, Jones NK, Forrest S, Young J, Pereira-Dias J, Hamilton WL,
Ferris M, et al: Screening of healthcare workers for SARS-CoV-2
highlights the role of asymptomatic carriage in COVID-19
transmission. Elife. 9:e587282020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pincus T, Swearingen CJ, Bergman M and
Yazici Y: RAPID3 (routine assessment of patient index data 3), a
rheumatoid arthritis index without formal joint counts for routine
care: Proposed severity categories compared to disease activity
score and clinical disease activity index categories. J Rheumatol.
35:2136–2147. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kane SP: Sample size calculator. ClinCalc.
https://clincalc.com/Stats/SampleSize.aspxJanuary
20–2021
|
|
27
|
Kang BS, Chung EY, Yun YP, Lee MK, Lee YR,
Lee KS, Min KR and Kim Y: Inhibitory effects of anti-inflammatory
drugs on interleukin-6 bioactivity. Biol Pharm Bull. 24:701–703.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao N, Di B and Xu LL: The NLRP3
inflammasome and COVID-19: Activation, pathogenesis and therapeutic
strategies. Cytokine Growth Factor Rev. 61:2–15. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Daniels MJ, Rivers-Auty J, Schilling T,
Spencer NG, Watremez W, Fasolino V, Booth SJ, White CS, Baldwin AG,
Freeman S, et al: Fenamate NSAIDs inhibit the NLRP3 inflammasome
and protect against Alzheimer's disease in rodent models. Nat
Commun. 7:125042016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rothan HA, Bahrani H, Abdulrahman AY,
Mohamed Z, Teoh TC, Othman S, Rashid NN, Rahman NA and Yusof R:
Mefenamic acid in combination with ribavirin shows significant
effects in reducing chikungunya virus infection in vitro and in
vivo. Antiviral Res. 127:50–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Etman MA, Farid RM, Nada AH and Ebian AA:
In vitro/in vivo correlation of fast release mephenamic acid
microspheres in humans. Med Princ Pract. 21:223–227. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shinkuma D, Hamaguchi T, Yamanaka Y and
Mizuno N: Correlation between dissolution rate and bioavailability
of different commercial mefenamic acid capsules. Int J Pharm.
21:187–200. 1984. View Article : Google Scholar
|
|
33
|
Baby K, Maity S, Mehta CH, Suresh A, Nayak
UY and Nayak Y: Targeting SARS-CoV-2 RNA-dependent RNA polymerase:
An in silico drug repurposing for COVID-19. F1000Res. 9:11662020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abdelnabi R, Foo CS, Kaptein SJ, Zhang X,
Do TN, Langendries L, Vangeel L, Breuer J, Pang J, Williams R, et
al: The combined treatment of molnupiravir and favipiravir results
in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster
infection model. EBioMedicine. 72:1035952021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guzman-Esquivel J, Mendoza-Hernandez MA,
Tiburcio-Jimenez D, Avila-Zamora ON, Delgado-Enciso J,
De-Leon-Zaragoza L, Casarez-Price JC, Rodriguez-Sanchez IP,
Martinez-Fierro ML, Meza-Robles C, et al: Decreased biochemical
progression in patients with castration-resistant prostate cancer
using a novel mefenamic acid anti-inflammatory therapy: A
randomized controlled trial. Oncol Lett. 19:4151–4160.
2020.PubMed/NCBI
|
|
36
|
Melnikov V, Tiburcio-Jimenez D,
Mendoza-Hernandez MA, Delgado-Enciso J, De-Leon-Zaragoza L,
Guzman-Esquivel J, Rodriguez-Sanchez IP, Martinez-Fierro ML,
Lara-Esqueda A, Delgado-Enciso OG, et al: Improve cognitive
impairment using mefenamic acid non-steroidal anti-inflammatory
therapy: Additional beneficial effect found in a controlled
clinical trial for prostate cancer therapy. Am J Transl Res.
13:4535–4543. 2021.PubMed/NCBI
|
|
37
|
Basri NI, Abd Ghani NA, Mahdy ZA, Abdul
Manaf MR and Mohamed Ismail NA: Celecoxib versus mefenamic acid in
the treatment of primary dysmenorrhea. Horm Mol Biol Clin Investig.
41:2020.PubMed/NCBI
|
